Medy-Tox Inc. (KOSDAQ: 086900)

Medy-Tox Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	246,252	221,121	195,096	184,870	140,828	205,900
Other Revenue	-	-	-0	-0	-	-
Revenue	246,252	221,121	195,096	184,870	140,828	205,900
Revenue Growth (YoY)	23.10%	13.34%	5.53%	31.27%	-31.60%	0.22%
Cost of Revenue	95,216	87,625	69,048	79,397	66,928	70,044
Gross Profit	151,036	133,496	126,048	105,473	73,900	135,856
Selling, General & Admin	102,062	86,605	47,679	41,938	59,544	67,725
Research & Development	25,133	25,133	23,324	23,267	32,544	27,016
Other Operating Expenses	1,322	1,322	1,242	1,216	1,403	1,225
Operating Expenses	131,630	116,173	79,383	72,335	110,969	110,167
Operating Income	19,406	17,322	46,665	33,138	-37,070	25,689
Interest Expense	-2,333	-2,333	-2,314	-4,781	-4,176	-2,081
Interest & Investment Income	896.43	896.43	610.76	957.22	340.02	338.87
Earnings From Equity Investments	1,246	1,363	5,129	-1,456	-2,432	2,371
Currency Exchange Gain (Loss)	475.22	475.22	3,425	2,111	-376.81	1,408
Other Non Operating Income (Expenses)	-5,565	-605.87	-715.84	108,431	6,967	-1,273
EBT Excluding Unusual Items	14,127	17,118	52,800	138,400	-36,748	26,453
Impairment of Goodwill	-	-	-	-	-711.12	-2,460
Gain (Loss) on Sale of Investments	-593.36	-593.36	-3,044	2,666	-1,067	2,231
Gain (Loss) on Sale of Assets	-671.97	-671.97	-230.42	131.48	58.63	-760.43
Asset Writedown	-	-	-	-12,932	-3,671	-313.35
Pretax Income	12,861	15,853	49,526	128,265	-42,139	25,150
Income Tax Expense	7,373	6,163	12,930	35,003	-12,100	-413.11
Earnings From Continuing Operations	5,488	9,690	36,596	93,263	-30,039	25,563
Minority Interest in Earnings	81.71	65.28	414.16	891.27	462.11	642.52
Net Income	5,570	9,755	37,010	94,154	-29,577	26,206
Preferred Dividends & Other Adjustments	975	975	975.33	974.73	0.7	-
Net Income to Common	4,595	8,780	36,035	93,179	-29,577	26,206
Net Income Growth	-79.26%	-73.64%	-60.69%	-	-	-62.54%
Shares Outstanding (Basic)	7	7	7	6	6	6
Shares Outstanding (Diluted)	7	7	7	6	6	6
Shares Change (YoY)	-49.34%	2.02%	2.28%	0.04%	-0.82%	2.75%
EPS (Basic)	670.93	1311.06	5491.68	14587.59	-4609.95	4050.83
EPS (Diluted)	670.87	1311.00	5489.34	14517.37	-4610.30	4050.83
EPS Growth	-64.95%	-76.12%	-62.19%	-	-	-63.55%
Free Cash Flow	2,901	5,862	16,304	2,452	-13,217	12,682
Free Cash Flow Per Share	423.59	875.31	2483.65	382.01	-2059.99	1960.41
Dividend Per Share	1100.000	1100.000	-	-	-	-
Gross Margin	61.33%	60.37%	64.61%	57.05%	52.48%	65.98%
Operating Margin	7.88%	7.83%	23.92%	17.93%	-26.32%	12.48%
Profit Margin	1.87%	3.97%	18.47%	50.40%	-21.00%	12.73%
Free Cash Flow Margin	1.18%	2.65%	8.36%	1.33%	-9.39%	6.16%
EBITDA	37,687	32,698	61,766	51,394	-18,472	43,830
EBITDA Margin	15.30%	14.79%	31.66%	27.80%	-13.12%	21.29%
D&A For EBITDA	18,280	15,376	15,101	18,256	18,597	18,141
EBIT	19,406	17,322	46,665	33,138	-37,070	25,689
EBIT Margin	7.88%	7.83%	23.92%	17.93%	-26.32%	12.48%
Effective Tax Rate	57.33%	38.88%	26.11%	27.29%	-	-
Advertising Expenses	-	5,976	3,351	2,031	3,839	8,228

Source: S&P Capital IQ. Standard template. Financial Sources.